Seiji Akiyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Seiji Akiyama has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Katsuki Ito
Department of Surgery II, School of Medicine, Nagoya University, Nagoya, Japan
15 shared publications Yasushi Kasai
10 shared publications- Akimasa Nakao
Department of Surgery, Nagoya Central Hospital, Nagoya, Japan
9 shared publications - Kenji Hibi
From the * Department of Surgery II, Nagoya University School of Medicine, Nagoya, Japan; and †Applied Chemistry, Nagoya Institute of Technology, Nagoya, Japan
9 shared publications Yasuhiro Kodera
7 shared publicationsHiroshi Nakayama
6 shared publications
Latest Publications
- 29 June 2007
- Vol. 27, 1459-63
A highly sensitive method for the detection of p16 methylation in the serum of colorectal cancer patients.
For the purpose of early detection of carcinomas, detection of p16 hypermethylation by methylation-specific polymerase chain reaction (MSP) in the serum of many kinds of malignancies has been introduced. An attempt to increase the sensitivity of this assay is reported for colorectal cancer. DNA samples were subjected to limiting dilution before being divided into ten smaller samples. Subsequently, hemi-nested MSP was performed on those ten samples. The limiting dilution-MSP (LD-MSP) provided a 10-fold increase in sensitivity of the detection of methylated DNA compared with conventional MSP. Of 44 colorectal cancer patients, 30 (68%) exhibited abnormal promoter methylation of p16 in their serum DNA by LD-MSP, while 13 (30%) exhibited it by conventional MSP. As a control, the serum DNA of 50 patients with colorectal carcinomas whose corresponding tumor DNA had no methylation in the p16 promoter was screened for aberrant methylation. No methylation was found in the serum DNA of this control group by LD-MSP or conventional MSP. The high sensitivity of LD-MSP makes it possible to detect smaller amounts of tumor DNA in the serum than conventional MSP. This technique also has great specificity and no abnormal methylation in serum has yet been observed if the corresponding tumor does not exhibit methylation. This observation supports the idea that LD-MSP could be applied in clinical use for the detection of tumor DNA in serum.
- 29 June 2007
- Vol. 27, 1459-63
A highly sensitive method for the detection of p16 methylation in the serum of colorectal cancer patients.
For the purpose of early detection of carcinomas, detection of p16 hypermethylation by methylation-specific polymerase chain reaction (MSP) in the serum of many kinds of malignancies has been introduced. An attempt to increase the sensitivity of this assay is reported for colorectal cancer. DNA samples were subjected to limiting dilution before being divided into ten smaller samples. Subsequently, hemi-nested MSP was performed on those ten samples. The limiting dilution-MSP (LD-MSP) provided a 10-fold increase in sensitivity of the detection of methylated DNA compared with conventional MSP. Of 44 colorectal cancer patients, 30 (68%) exhibited abnormal promoter methylation of p16 in their serum DNA by LD-MSP, while 13 (30%) exhibited it by conventional MSP. As a control, the serum DNA of 50 patients with colorectal carcinomas whose corresponding tumor DNA had no methylation in the p16 promoter was screened for aberrant methylation. No methylation was found in the serum DNA of this control group by LD-MSP or conventional MSP. The high sensitivity of LD-MSP makes it possible to detect smaller amounts of tumor DNA in the serum than conventional MSP. This technique also has great specificity and no abnormal methylation in serum has yet been observed if the corresponding tumor does not exhibit methylation. This observation supports the idea that LD-MSP could be applied in clinical use for the detection of tumor DNA in serum.
- 26 September 2006
- Vol. 53 (70) , 648-50
Laparoscopy-assisted total gastrectomy for a case of MALT lymphoma: a case report.
A case of laparoscopy-assisted total gastrectomy with regional lymph node dissection for MALT (mucosa-associated lymphoid tissue) lymphoma is reported. The patient was a 45-year-old male with MALT lymphoma. Eradication of Helicobacter pylori as the initial therapy had failed to halt progression of the tumor. Considering certainty of the second therapy, he was transferred to surgical treatment. Total gastrectomy was required and this was performed by the laparoscopy-assisted approach. The postoperative course was satisfactory and the patient has been disease-free for 5 years after the operation. Laparoscopic operation could be a useful option in the second-line treatment for MALT lymphoma after failure to eradicate H. pylori.
- 26 September 2006
- Vol. 53 (70) , 648-50
Laparoscopy-assisted total gastrectomy for a case of MALT lymphoma: a case report.
A case of laparoscopy-assisted total gastrectomy with regional lymph node dissection for MALT (mucosa-associated lymphoid tissue) lymphoma is reported. The patient was a 45-year-old male with MALT lymphoma. Eradication of Helicobacter pylori as the initial therapy had failed to halt progression of the tumor. Considering certainty of the second therapy, he was transferred to surgical treatment. Total gastrectomy was required and this was performed by the laparoscopy-assisted approach. The postoperative course was satisfactory and the patient has been disease-free for 5 years after the operation. Laparoscopic operation could be a useful option in the second-line treatment for MALT lymphoma after failure to eradicate H. pylori.
- 11 July 2006
- Vol. 26, 2029-32
TAOS1, a novel marker for advanced esophageal squamous cell carcinoma.
TAOS1 (tumor amplified and overexpressed sequence 1) was recently cloned and found to be possibly important in driving the amplification of 11q13 in oral squamous cell carcinoma (SCC). Quantitative RT-PCR was performed to determine the possible relationship between TAOS1 gene expression levels and clinicopathological features in esophageal SCC. TAOS1 overexpression was observed in 7 out of 38 (18%) esophageal SCCs and CCND1 overexpression was observed in 4 out of 38 (11%), suggesting that TAOS1 was more frequently overexpressed than CCND1 in esophageal SCC. The examination of the correlation of TAOS1 overexpression with the clinicopathological features revealed a significant difference in lymph node metastasis (p = 0.014) and a trend towards advanced TNM stages (p = 0.074). The present results suggest that TAOS1 might serve as a new marker for predicting the malignancy of esophageal SCC.
- 11 July 2006
- Vol. 26, 2029-32
TAOS1, a novel marker for advanced esophageal squamous cell carcinoma.
TAOS1 (tumor amplified and overexpressed sequence 1) was recently cloned and found to be possibly important in driving the amplification of 11q13 in oral squamous cell carcinoma (SCC). Quantitative RT-PCR was performed to determine the possible relationship between TAOS1 gene expression levels and clinicopathological features in esophageal SCC. TAOS1 overexpression was observed in 7 out of 38 (18%) esophageal SCCs and CCND1 overexpression was observed in 4 out of 38 (11%), suggesting that TAOS1 was more frequently overexpressed than CCND1 in esophageal SCC. The examination of the correlation of TAOS1 overexpression with the clinicopathological features revealed a significant difference in lymph node metastasis (p = 0.014) and a trend towards advanced TNM stages (p = 0.074). The present results suggest that TAOS1 might serve as a new marker for predicting the malignancy of esophageal SCC.
- 9 July 2004
- Vol. 51 (58) , 1225-8
Obesity and outcome of distal gastrectomy with D2 lymphadenectomy for carcinoma.
Obesity has correlated with surgical outcome in patients undergoing elective surgery for various cancers. This relationship has not been examined for gastric cancer surgery performed at a specialized high-volume center. Data from 562 consecutive patients treated with potentially curative distal gastrectomy between 1993 and 1999 were used. Patients were assigned to 2 groups according to a combination of Japanese and Western criteria for obesity (group A, body mass index < 25 for men and < 22 for women; or group B, body mass index > or = 27). Relationships between obesity and clinical variables were analyzed. Two hundred and five patients (29.4%) were obese by Japanese cutoff values; only 50 (7.2%) were obese by Western standards. A significant difference in blood loss and operative time was noted between groups. Intra-abdominal infection was more frequent for group B, leading to significantly longer hospitalization. Lymph node yield was significantly smaller in group B, but no influence of obesity on long-term survival was observed. Obesity can increase duration of surgery, volume of blood loss, and incidence of surgical complications, but does not affect long-term survival.
- 9 July 2004
- Vol. 51 (58) , 1225-8
Obesity and outcome of distal gastrectomy with D2 lymphadenectomy for carcinoma.
Obesity has correlated with surgical outcome in patients undergoing elective surgery for various cancers. This relationship has not been examined for gastric cancer surgery performed at a specialized high-volume center. Data from 562 consecutive patients treated with potentially curative distal gastrectomy between 1993 and 1999 were used. Patients were assigned to 2 groups according to a combination of Japanese and Western criteria for obesity (group A, body mass index < 25 for men and < 22 for women; or group B, body mass index > or = 27). Relationships between obesity and clinical variables were analyzed. Two hundred and five patients (29.4%) were obese by Japanese cutoff values; only 50 (7.2%) were obese by Western standards. A significant difference in blood loss and operative time was noted between groups. Intra-abdominal infection was more frequent for group B, leading to significantly longer hospitalization. Lymph node yield was significantly smaller in group B, but no influence of obesity on long-term survival was observed. Obesity can increase duration of surgery, volume of blood loss, and incidence of surgical complications, but does not affect long-term survival.
- 1 May 2004
- Vol. 67, 9-15
Prolonged cytostatic tumor dormancy induced by serial exchange of chemotherapy in colorectal carcinoma.
To improve quality of life cytostatic effect of serially changed chemotherapy was investigated. Nonrandomized controlled trial in 17 patients with diagnosis of metastasis or recurrence following primary colorectal carcinoma was conducted from 1996 through 2001. Patients underwent low-dose CDDP+5-FU monitoring continual CEA level. Whenever uninterrupted increase for minimally 3 times of CEA level was observed, the next chemotherapy was chosen from the following chemotherapy: l-Leucovorin+5-FU, low-dose CPT-11. Six were died of carcinoma. Median survival time from primary surgery and those from the day of diagnosis of metastasis were 48.6 and 23.3 months, respectively. Most of the patients experienced decrease in CEA level after continuous increase. No severe side effects were observed in them except one who died of hyperosmolar diabetic syndrome. Although the present trial should await further follow-up to confirm the clinical relevance of its modality, longer survival attained by the serially exchanged chemotherapy would implicate future chemotherapeutic strategy.
- 1 May 2004
- Vol. 67, 9-15
Prolonged cytostatic tumor dormancy induced by serial exchange of chemotherapy in colorectal carcinoma.
To improve quality of life cytostatic effect of serially changed chemotherapy was investigated. Nonrandomized controlled trial in 17 patients with diagnosis of metastasis or recurrence following primary colorectal carcinoma was conducted from 1996 through 2001. Patients underwent low-dose CDDP+5-FU monitoring continual CEA level. Whenever uninterrupted increase for minimally 3 times of CEA level was observed, the next chemotherapy was chosen from the following chemotherapy: l-Leucovorin+5-FU, low-dose CPT-11. Six were died of carcinoma. Median survival time from primary surgery and those from the day of diagnosis of metastasis were 48.6 and 23.3 months, respectively. Most of the patients experienced decrease in CEA level after continuous increase. No severe side effects were observed in them except one who died of hyperosmolar diabetic syndrome. Although the present trial should await further follow-up to confirm the clinical relevance of its modality, longer survival attained by the serially exchanged chemotherapy would implicate future chemotherapeutic strategy.
- 24 October 2003
- Vol. 50 (53) , 1278-80
PGP9.5 overexpression in esophageal squamous cell carcinoma.
PGP9.5 is a ubiquitin hydrolase widely expressed in neuronal tissue at all stages of neuronal differentiation and has been used as a neuroendocrine marker. Recently, it has been proved that PGP9.5 expression was highly observed in squamous cell carcinoma of lung cancer, suggesting that it might be a tumor marker for squamous cell carcinoma. To better characterize its role in digestive tract cancers, we examined PGP9.5 expression retrospectively in esophageal cancers. We examined PGP9.5 expression retrospectively in 40 resected esophageal cancers (squamous cell carcinoma) and 10 gastric cancers (adenocarcinoma) using immunohistochemistry. Of 40 esophageal cancer specimens, 19 (48%) exhibited positive staining with PGP9.5 in most tumor cells, while no PGP9.5 expression was observed in any of the 10 gastric cancers. Although the precise mechanism underlying the effect of PGP9.5 on oncogenicity remains to be proven, it was confirmed that it may be a potential marker for esophageal squamous cell carcinoma.
- 24 October 2003
- Vol. 50 (53) , 1278-80
PGP9.5 overexpression in esophageal squamous cell carcinoma.
PGP9.5 is a ubiquitin hydrolase widely expressed in neuronal tissue at all stages of neuronal differentiation and has been used as a neuroendocrine marker. Recently, it has been proved that PGP9.5 expression was highly observed in squamous cell carcinoma of lung cancer, suggesting that it might be a tumor marker for squamous cell carcinoma. To better characterize its role in digestive tract cancers, we examined PGP9.5 expression retrospectively in esophageal cancers. We examined PGP9.5 expression retrospectively in 40 resected esophageal cancers (squamous cell carcinoma) and 10 gastric cancers (adenocarcinoma) using immunohistochemistry. Of 40 esophageal cancer specimens, 19 (48%) exhibited positive staining with PGP9.5 in most tumor cells, while no PGP9.5 expression was observed in any of the 10 gastric cancers. Although the precise mechanism underlying the effect of PGP9.5 on oncogenicity remains to be proven, it was confirmed that it may be a potential marker for esophageal squamous cell carcinoma.
- 15 September 2003
- Vol. 9 (11) , 4282-5
Identification of S100A2 as a target of the DeltaNp63 oncogenic pathway.
It has been proved recently that DeltaNp63 may play an oncogenic role in the tumorigenic pathway of squamous cell cancers. To gain additional insight into this pathway, we examined global patterns of gene expression in cancer cells after DeltaNp63 gene introduction using the oligonucleotide microarray approach. We found that S100A2 might be a target of the DeltaNp63 pathway. To confirm the data obtained from oligonucleotide microarray, we then examined the interaction of DeltaNp63 to S100A2. S100A2 induction was strictly dependent on DeltaNp63 expression by DeltaNp63 transgene and Northern analysis. DeltaNp63 transactivated the S100A2 promoter, and significantly more fold changes were seen in DeltaNp63-introduced cells than in p53-introduced cells, suggesting that DeltaNp63 may be a novel stimulator of the S100A2 promoter. Taken together, this evidence would seem to suggest that S100A2 is a novel downstream mediator of DeltaNp63.
- 15 September 2003
- Vol. 9 (11) , 4282-5
Identification of S100A2 as a target of the DeltaNp63 oncogenic pathway.
It has been proved recently that DeltaNp63 may play an oncogenic role in the tumorigenic pathway of squamous cell cancers. To gain additional insight into this pathway, we examined global patterns of gene expression in cancer cells after DeltaNp63 gene introduction using the oligonucleotide microarray approach. We found that S100A2 might be a target of the DeltaNp63 pathway. To confirm the data obtained from oligonucleotide microarray, we then examined the interaction of DeltaNp63 to S100A2. S100A2 induction was strictly dependent on DeltaNp63 expression by DeltaNp63 transgene and Northern analysis. DeltaNp63 transactivated the S100A2 promoter, and significantly more fold changes were seen in DeltaNp63-introduced cells than in p53-introduced cells, suggesting that DeltaNp63 may be a novel stimulator of the S100A2 promoter. Taken together, this evidence would seem to suggest that S100A2 is a novel downstream mediator of DeltaNp63.
- 17 March 2003
- Published by Wiley in International Journal of Cancer
- Vol. 105 (4) , 491-493
Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients
We previously proved that p16 promoter methylation present in the tumors of colorectal cancer patients can be detected in the serum of those same patients using methylation‐specific PCR (MSP). To seek the possibility that this technique could be applied to the monitoring of cancer recurrence, we examined the p16 methylation using MSP. We detected tumor DNA in the serum of 31 of 45 (69%) patients with recurrent colorectal cancer. No methylation was found in serum DNA of 50 patients with colorectal cancers whose corresponding tumor DNA had no methylation in p16 promoter. These results suggested that MSP might be a sensitive and useful method to detect recurrent colorectal cancer in serum.
- 17 March 2003
- Published by Wiley in International Journal of Cancer
- Vol. 105 (4) , 491-493
Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients
We previously proved that p16 promoter methylation present in the tumors of colorectal cancer patients can be detected in the serum of those same patients using methylation‐specific PCR (MSP). To seek the possibility that this technique could be applied to the monitoring of cancer recurrence, we examined the p16 methylation using MSP. We detected tumor DNA in the serum of 31 of 45 (69%) patients with recurrent colorectal cancer. No methylation was found in serum DNA of 50 patients with colorectal cancers whose corresponding tumor DNA had no methylation in p16 promoter. These results suggested that MSP might be a sensitive and useful method to detect recurrent colorectal cancer in serum.
- 1 March 2003
- Vol. 9 (3) , 1053-6
A cancer-prone case with a background of methylation of p16 tumor suppressor gene.
To date, the presence of p16 gene promoter methylation associated with loss of protein expression has been demonstrated frequently in digestive tract cancers. In this study, we tested for the methylation status of p16 promoter in normal tissue specimens using the methylation-specific PCR technique to examine whether p16 methylation already existed in the background of tumors. Aberrant promoter methylation of p16 gene was detected in 1 of 40 esophageal and 1 of 69 gastric and no colorectal epithelium specimens, and these 2 specimens were derived from the same patient. We also found the same methylation change in both tumor and blood cell DNA. These results suggested that the p16 gene was inactivated by methylation in normal background cells of this patient and that other additional factors may promote tumor development in his esophageal and gastric tissues.
- 1 March 2003
- Vol. 9 (3) , 1053-6
A cancer-prone case with a background of methylation of p16 tumor suppressor gene.
To date, the presence of p16 gene promoter methylation associated with loss of protein expression has been demonstrated frequently in digestive tract cancers. In this study, we tested for the methylation status of p16 promoter in normal tissue specimens using the methylation-specific PCR technique to examine whether p16 methylation already existed in the background of tumors. Aberrant promoter methylation of p16 gene was detected in 1 of 40 esophageal and 1 of 69 gastric and no colorectal epithelium specimens, and these 2 specimens were derived from the same patient. We also found the same methylation change in both tumor and blood cell DNA. These results suggested that the p16 gene was inactivated by methylation in normal background cells of this patient and that other additional factors may promote tumor development in his esophageal and gastric tissues.
- Open Access
- 21 January 2003
- Published by Wiley in International Journal of Cancer
- Vol. 104 (4) , 433-436
Methylation pattern of HLTF gene in digestive tract cancers
Recently, the loss of helicase-like transcription factor (HLTF) gene expression accompanied by HLTF promoter methylation was identified in colon cancers. We examined HLTF methylation in colorectal, gastric and esophageal carcinomas. Twenty-five of 76 colorectal cancers (33%), 11 of 65 gastric cancers (17%), and 1 of 40 esophageal cancers (3%) demonstrated abnormal methylation of the HLTF promoter. Abnormal methylation was found in the tumors of patients at all clinical stages, suggesting that these cancers could be methylated from an early stage. These results suggested that HLTF might play a variety of roles depending on the tissue type and could be inactivated at an early stage in the tumorigenic pathway.
- 21 January 2003
- Published by Wiley in International Journal of Cancer
- Vol. 104 (4) , 433-436
Open AccessMethylation pattern of HLTF gene in digestive tract cancers
Recently, the loss of helicase-like transcription factor (HLTF) gene expression accompanied by HLTF promoter methylation was identified in colon cancers. We examined HLTF methylation in colorectal, gastric and esophageal carcinomas. Twenty-five of 76 colorectal cancers (33%), 11 of 65 gastric cancers (17%), and 1 of 40 esophageal cancers (3%) demonstrated abnormal methylation of the HLTF promoter. Abnormal methylation was found in the tumors of patients at all clinical stages, suggesting that these cancers could be methylated from an early stage. These results suggested that HLTF might play a variety of roles depending on the tissue type and could be inactivated at an early stage in the tumorigenic pathway.